Response to peginterferon-alpha 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 1

Hepatology International

Volumn 7, Issue 1, 2013, Pages 144-152

  Miyauchi, Tomoo ^a   Kanda, Tatsuo ^a   Imazeki, Fumio ^a   Mikata, Rintaro ^a   Tawada, Akinobu ^a   Arai, Makoto ^a   Fujiwara, Keiichi ^a   Nakamoto, Shingo ^a   Wu, Shuang ^a   Tanaka, Takeshi ^a   Miyamura, Tatsuo ^a   Kimura, Michio ^b   Hirai, Yasuo ^c   Takashi, Motohide ^d   Mikami, Shigeru ^e   Sugiura, Nobuyuki ^f   Natsuki, Yutaka ^g   Azemoto, Ryosaku ^h   Suzuki, Noriaki ^h   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY   (Japan)

^b Social Insurance Funabashi Chuo Hospital   (Japan)

^c Matsudo City Hospital   (Japan)

^d Saiseikai Narashino Hospital   (Japan)

^e Kikkoman Hospital   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION CHIBA MEDICAL CENTER   (Japan)

^g Sannou Hospital Medical Center   (Japan)

^h KIMITSU CHUO HOSPITAL   (Japan)

Author keywords

Age; Gender; Genotype 1; HCV; Ribavirin

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN; SODIUM CHLORIDE; VIRUS RNA;

ADULT; AGED; ANEMIA; ARTICLE; BRAIN INFARCTION; DEPRESSION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FACIAL NERVE PARALYSIS; FAINTNESS; FEMALE; FOLLOW UP; GENOTYPE; HEART PALPITATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSOMNIA; INTERSTITIAL PNEUMONIA; JAPAN; JAPANESE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POOR EYESIGHT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN DISEASE; THROMBOCYTE; TREATMENT OUTCOME;

EID: 84875268532     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-012-9349-4     Document Type: Article

References (36)

1. AM Di Bisceglie 1997 Hepatitis C and hepatocellular carcinoma Hepatology 26 S34 S38 10.1002/hep.510260706
2. AM Di Bisceglie JH Hoofnagle 2002 Optimal therapy of hepatitis C Hepatology 36 S121 S127 12407585 10.1002/hep.1840360716
3. P Simmonds J Bukh C Combet, et al. 2005 Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes Hepatology 42 962 973 16149085 10.1002/hep.20819 1:CAS:528:DC%2BD2MXhtFGlsbbI
4. T Kanda F Imazeki O Yokosuka 2010 New antiviral therapies for chronic hepatitis C Hepatol Int 4 548 561 21063477 10.1007/s12072-010-9193-3
5. T Kanda F Imazeki R Azemoto, et al. 2011 Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2 Dig Dis Sci 56 3335 3342 21604145 10.1007/s10620-011-1750-7 1:CAS:528: DC%2BC3MXhsVCksbnP
6. Y Tanaka K Hanada M Mizokami, et al. 2002 A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades Proc Natl Acad Sci USA 99 15584 15589 12438687 10.1073/pnas.242608099 1:CAS:528:DC%2BD3sXjvVyl
7. Y Iwasaki H Ikeda Y Araki, et al. 2006 Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C Hepatology 43 54 63 16374855 10.1002/hep.20984 1:CAS:528:DC%2BD28Xpt1Sgsw%3D%3D
8. CF Huang JF Yang CY Dai, et al. 2010 Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C J Infect Dis 201 751 759 20102281 10.1086/650470 1:CAS:528:DC%2BC3cXkt1amtLw%3D
9. EG Giannini M Basso V Savarino A Picciotto 2010 Predictive factors for response to peginterferon-alpha and ribavirin treatment of chronic HCV infection in patients aged 65 years and more Dig Dis Sci 55 3193 3199 20848200 10.1007/s10620-010-1408-x
10. H Sezaki F Suzuki Y Kawamura, et al. 2009 Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads Dig Dis Sci 54 1317 1324 18958621 10.1007/s10620-008-0500-y 1:CAS:528:DC%2BD1MXlsFKrtLY%3D
11. JL Narciso-Schiavon LS Lde RJ Carvalho-Filho, et al. 2010 Gender influence on treatment of chronic hepatitis C genotype 1 Rev Soc Bras Med Trop 43 217 223 20563484 10.1590/S0037-86822010000300001
12. AM Di Bisceglie X Fan T Chambers J Strinko 2006 Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: the null responder J Med Virol 78 446 451 16566033 10.1002/jmv.20560
13. S Nakamoto F Imazeki T Kanda, et al. 2011 The efficacy of peginterferon and ribavirin combination therapy in elderly patients with chronic hepatitis C Nippon Koreisha Syokakibyo Gakkai Zasshi 13 162 169 (In Japanese with English abstract)
14. T Kanda F Imazeki Y Yonemitsu, et al. 2011 Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test J Viral Hepat 18 e292 e297 21129130 10.1111/j.1365-2893. 2010.01409.x 1:STN:280:DC%2BC3Mjkslyisg%3D%3D
15. T Tanaka K Tsukiyama-Kohara K Yamaguchi, et al. 1994 Significance of specific antibody assay for genotyping of hepatitis C virus Hepatology 19 1347 1353 7514558 10.1002/hep.1840190605 1:CAS:528:DyaK2MXkt1Chsw%3D%3D
16. H Okamoto Y Sugiyama S Okada, et al. 1992 Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources J Gen Virol 73 673 679 1312125 10.1099/0022-1317-73-3-673 1:CAS:528:DyaK38XisV2msbk%3D
17. P Simmonds F McOmish PL Yap, et al. 1993 Sequence variability in the 5′ non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity J Gen Virol 74 661 668 8385694 10.1099/0022-1317-74-4-661 1:CAS:528:DyaK3sXit1Oht7Y%3D
18. H Chung T Ueda M Kudo 2010 Changing trends in hepatitis C infection over the past 50 years in Japan Intervirology 53 39 43 20068339 10.1159/000252782
19. T Oze N Hiramatsu T Yakushijin, et al. 2011 Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy J Hepatol 54 604 611 21145907 10.1016/j.jhep.2010. 07.043 1:CAS:528:DC%2BC3MXjs12iurc%3D
20. T Honda Y Katano J Shimizu, et al. 2010 Efficacy of peginterferon-alpha- 2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C Liver Int 30 527 537 19523048 10.1111/j.1478-3231.2009.02064.x 1:CAS:528:DC%2BC3cXkt1amurc%3D
21. N Hiramatsu T Oze N Tsuda, et al. 2006 Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy? Hepatol Res 35 185 189 16678478 1:CAS:528:DC%2BD28XmslGqtLk%3D
22. Ebinuma H, Saito H, Tada S et al. Disadvantages of peginterferon and ribavirin treatment in older patients with chronic hepatitis C: an analysis using the propensity score. Hepatol Int 2011 (Epub ahead of print)
23. G Antonucci MA Longo C Angeletti, et al. 2007 The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 years Am J Gastroenterol 102 1383 1391 17403072 10.1111/j.1572-0241.2007.01201.x 1:CAS:528:DC%2BD2sXoslGlt7k%3D
24. M Kainuma N Furusyo E Kajiwara, et al. 2010 Pegylated interferon alpha-2b plus ribavirin for older patients with chronic hepatitis C World J Gastroenterol 16 4400 4409 20845506 10.3748/wjg.v16.i35.4400 1:CAS:528:DC%2BC3cXhtF2rsLvJ
25. M Lindh B Arnholm A Eilard, et al. 2011 Hepatitis C treatment response kinetics and impact of baseline predictors J Viral Hepat 18 400 407 20500548 10.1111/j.1365-2893.2010.01323.x 1:STN:280:DC%2BC3MrovFWmsw%3D%3D
26. M Deschenes VG Bain SS Lee, et al. 2010 Identifying HCV genotype 1 patients at risk of relapse Eur J Gastroenterol Hepatol 22 546 551 20216320 10.1097/MEG.0b013e32832d237d
27. D Ge J Fellay AJ Thompson, et al. 2009 Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 399 401 19684573 10.1038/nature08309 1:CAS:528:DC%2BD1MXpvFCrtbw%3D
28. V Suppiah M Moldovan G Ahlenstiel, et al. 2009 IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy Nat Genet 41 1100 1104 19749758 10.1038/ng.447 1:CAS:528:DC%2BD1MXhtFaju7%2FM
29. Y Tanaka N Nishida M Sugiyama, et al. 2009 Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C Nat Genet 41 1105 1109 19749757 10.1038/ng.449 1:CAS:528:DC%2BD1MXhtFaju73K
30. S Nakamoto T Kanda F Imazeki, et al. 2011 Simple assay based on restriction fragment length polymorphism associated with IL28B in chronic hepatitis C patients Scand J Gastroenterol 46 955 961 21529139 10.3109/00365521.2011.574731 1:CAS:528:DC%2BC3MXoslOhtL8%3D
31. JG McHutchison M Manns K Patel, et al. 2002 Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C Gastroenterology 123 1061 1069 12360468 10.1053/gast.2002.35950 1:CAS:528:DC%2BD38Xotl2gurk%3D
32. F Morisco T Stroffolini E Medda, et al. 2010 Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combined therapy (PEG-IFN and ribavirin): NADIR study J Viral Hepat 17 427 434 19780939 10.1111/j.1365-2893. 2009.01200.x 1:STN:280:DC%2BC3crksV2rtg%3D%3D
33. D Jensen 2011 A new era of hepatitis C therapy begins N Engl J Med 364 1272 1274 21449791 10.1056/NEJMe1100829 1:CAS:528:DC%2BC3MXkt1Cgs70%3D
34. H Kumada J Toyoda T Okanoue K Chayama H Tsubouchi N Hayashi 2012 Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan J Hepatol 56 78 84 21827730 10.1016/j.jhep.2011.07.016 1:CAS:528:DC%2BC3MXhs1GhsbbM
35. P Cacoub M Bourliere J Lubbe, et al. 2012 Dermatological side effects of hepatitis C and its treatment: Patient management in the era of direct-acting antivirals J Hepatol 56 455 463 21884670 10.1016/j.jhep.2011.08.006 1:CAS:528:DC%2BC38XpsFyhsw%3D%3D
36. K Seden D Back 2011 Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions Curr Opin HIV AIDS 6 514 526 22001895 10.1097/COH.0b013e32834b54dc